FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

77acimigton, 270. 200.0

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

HOUG	nd Address of EN ELIZ		2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC IONS									k all applic Directo	· ·		wner					
(Last) C/O ION 2855 GA	12/	3. Date of Earliest Transaction (Month/Day/Year) 12/15/2017									SVP, Finance & CFO									
(Street) CARLSBAD CA 92010						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	Form f	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S																			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)						ion 2A. Deemed Execution Date,			3. Transa Code (8)	ction	4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			or 5. Amo and 5) Securit Benefic		int of es ially Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) or (D)	Price	Trans		action(s) 3 and 4)			(Instr. 4)			
Common	Stock	2017	.017 12		12/15/2017			5,000(1)) A	\$10	0.29 15,392		,392	D						
Common	2017	.017 12/		2017	S ⁽¹⁾		5,000(1)	D	\$52	2.55 ⁽²⁾ 10		0,392		D						
		Т	able II								oosed of converti	•		•	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Execution if any (Month/E	on Date,	4. Transa Code (8)		n of l		6. Date Exercis Expiration Date (Month/Day/Yea		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D S (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owner Form Direct or Ind (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisa		Expiration Date	Title	Amou or Numb of Share	er						
Employee Stock Option	\$10.29	12/15/2017	12/15	5/2017	M			5,000	01/03/20	015	01/02/2018	Common Stock	5,00	00	\$0	0		D		

Explanation of Responses:

- 1. Acquired as a result of exercising a stock option that was scheduled to expire on 1/2/2018. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 2/3/2015.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$52.34 to \$52.65, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

Remarks:

buv)

/s/Elizabeth L. Hougen 12/18/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.